Asia's Biggest Drugmaker Eyes Greener Shores as Fortunes Fade at HomeBy
The balmy summer evening last year saw some of the most prolific biotech and scientific minds of Boston come together. There was the provost of MIT, enjoying the saxophone music alongside a U.S. congressman and senior venture capitalists. Their hosts: the Frenchman and the American tasked with turning around the fortunes of Asia’s largest drugmaker, Takeda Pharmaceutical Co.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- One of the World’s Hottest Stocks Is Now Tumbling
- This Rare Bear Who Called the Crash Warns Housing Is Too Hot Again
- Recent ‘Odd’ Market Moves May Be a Warning Sign for Stocks
- The Global Economy Is Doing Just Fine, But the Davos Elite Is Worried
- U.S. Stocks Gain as Senate Votes to End Shutdown: Markets Wrap